CJC-1295 (No DAC) + Ipamorelin 5/5 mg

CJC-1295 (No DAC) + Ipamorelin 5/5 mg for research: identity and specifications

This presentation combines CJC-1295 without DAC and Ipamorelin in a single vial: a short half-life GHRH analog and a ghrelin-mimetic secretagogue. It is supplied as a lyophilized powder, purified by HPLC.

Scientific context

In experimental models, the combination is studied in somatotropic axis signaling pathways, including the pulsatile release of growth hormone associated with the combined action of GHRH and ghrelin secretagogues. These are observations in experimental models, with no inference of effects in humans.

Technical specifications

Frequently asked questions

Why combine CJC-1295 without DAC and Ipamorelin in the same vial?

The two compounds act through complementary mechanisms on the somatotropic axis and are studied together in experimental models of pulsatile growth hormone release.

What is the certified purity of this lot?

The combined purity is verified by HPLC and reported in the COA for lot IPCJ12092025-J.

How should this material be stored before use?

Kept at -20 °C, protected from light and moisture, in the original sealed packaging.

Is this material intended for human or veterinary use?

No. The material is supplied exclusively for in vitro laboratory research, with no indication for human, veterinary, diagnostic or therapeutic use.

See: Peptide encyclopedia entry and How every lot is tested (HPLC, COA).

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition.